Roycederm Seborrheic Dermatitis And Psoriasis Treatment Cream
NDC 85424-014
Product Information
Roycederm Seborrheic Dermatitis And Psoriasis Treatment Cream (salicylic acid 3%) is a OTC MONOGRAPH DRUG-approved product labeled by Roycederm Llc. This medication is used on the skin to treat common skin and foot (plantar) warts. It is supplied as a cream for topical administration. This product entry covers the primary NDC 85424-014 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 85424-014?
What are the uses of this product?
What are Active Ingredients of this product?
- SALICYLIC ACID 3 g/100g - A compound obtained from the bark of the white willow and wintergreen leaves. It has bacteriostatic, fungicidal, and keratolytic actions.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- SALICYLIC ACID (UNII: O414PZ4LPZ)
- SALICYLIC ACID (UNII: O414PZ4LPZ) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- WATER (UNII: 059QF0KO0R)
- BASSIA SCOPARIA FRUIT (UNII: 04W97Z676Y)
- DICTAMNUS DASYCARPUS ROOT BARK (UNII: LA97176ILS)
- SMILAX GLABRA WHOLE (UNII: H51N91QNEB)
- SOPHORA FLAVESCENS ROOT (UNII: IYR6K8KQ5K)
- CNIDIUM MONNIERI FRUIT OIL (UNII: JK0MS9P8YL)
- PHELLODENDRON AMURENSE BARK (UNII: PBG27B754G)
- ARTEMISIA VULGARIS OIL (UNII: 72Q967Y48V)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 416910 - salicylic acid 3 % Topical Cream
- RxCUI: 416910 - salicylic acid 30 MG/ML Topical Cream
* Please review the full disclaimer at the bottom of this page.